# Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

> **NCT07148206** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Montefiore Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Dronabinol Capsules
- **DRUG:** Epidiolex 100 mg/mL Oral Solution
- **OTHER:** Placebo Dronabinol
- **OTHER:** Placebo Epidiolex

## Key facts

- **NCT ID:** NCT07148206
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148206, "Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07148206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*